Table 2

Summary estimates of test characteristics of interferon-gamma release assays and tuberculin skin tests based on adult studies using non-tuberculosis patients as controls

TestsSets of dataCasesControlsMethod of meta-analysisMean sensitivity % (95% CI)Mean specificity % (95% CI)Mean PLR (95% CI)Mean NLR (95% CI)Mean DOR (95% CI)
QFT-G (E1, E4, E5, E19–E26)11551679Bivariate random effects model86 (81 to 90)76 (66 to 83)3.6 (2.3 to 5.6)0.18 (0.12 to 0.27)19.6 (10.7 to 36.2)
Univariate random effects model86 (82 to 91)77 (70 to 85)3.6 (2.5 to 5.1)0.19 (0.13 to 0.28)21.3 (11.4 to 39.8)
QFT-G-IT (E13, E27–E30)5307266Bivariate random effects model75 (64 to 84)64 (47 to 78)2.1 (1.1 to 4.0)0.38 (0.22 to 0.68)5.5 (2.3 to 13.1)
Univariate random effects model75 (64 to 86)66 (55 to 78)2.0 (1.3 to 3.1)0.38 (0.23 to 0.63)5.7 (2.6 to 12.3)
T-SPOT.TB (based on studies with mean or median age >47.1 years) (E16, E31, E34, E36, E37)6236194Bivariate random effects model91 (85 to 95)80 (67 to 89)4.7 (2.4 to 9.1)0.11 (0.06 to 0.20)43.9 (17.2 to 111.9)
Univariate random effects model93 (88 to 98)77 (67 to 87)4.4 (2.7 to 7.4)0.11 (0.06 to 0.20)52.0 (26.1 to 103.6)
T-SPOT.TB (based on studies with mean or median age ≤47.1 years) (E20, E21, E27, E32, E33, E35)6179218Bivariate random effects model87 (79 to 93)61 (46 to 75)2.3 (1.3 to 4.0)0.20 (0.10 to 0.40)11.1 (4.6 to 26.8)
Univariate random effects model87 (85 to 90)57 (47 to 66)2.2 (1.7 to 2.9)0.24 (0.16 to 0.36)10.0 (5.2 to 19.3)
TST-BCG (10 mm) (E5, E26, E34, E35, E37)6193280Bivariate random effects model57 (44 to 68)68 (54 to 80)1.8 (1.0 to 3.3)0.63 (0.39 to 1.03)2.8 (1.3 to 6.2)
Univariate random effects model59 (48 to 69)62 (46 to 79)1.8 (1.2 to 2.7)0.66 (0.54 to 0.80)2.8 (1.6 to 5.2)
  • DOR, diagnostic odds ratio; NLR, negative likelihood ratio; NA, not applicable; PLR, positive likelihood ratio; QFT-G, QuantiFERON-TB Gold; QFT-G-IT, QuantiFERON-TB Gold in-Tube; TST-BCG (x mm), tuberculin skin test with cut-off at x mm among predominantly BCG-vaccinated subjects.